This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.

Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company’s financial results is included in the Company’s Form 10-K for the year ended December 31, 2009, and subsequent SEC filings.
Leading National Lab Provider

- Fastest growing national lab
- $55 billion market
- Clinical, Anatomic and Genomic Testing
- Serving clients in all 50 states and Canada
- Foremost clinical trials testing business
Introduction

Laboratory Testing

- Prevention and Wellness Monitoring
- Preliminary Risk Assessment
- Diagnosis
- Secondary Assessment of Prognosis
- Clinical Decision Regarding Treatment Path
- Monitoring and Management of Condition

Health Care Continuum

Source: Deloitte (OAML)
Valuable Service
• Small component of total cost influences large percentage of clinical decisions
• Screening, early detection, and monitoring reduce downstream costs
• Companion diagnostics improve drug efficacy and reduce adverse drug effects

2010 Projected US Health Care Spend $2.6 Trillion

- 2-3% of spend influences 70-80% of physician decisions

Growth Drivers

- Aging population
- Industry consolidation
- Advances in genomics
- Pharmacogenomics / companion diagnostics
- Cost pressures

Source: CDC National Ambulatory Medical Care Survey and Company Estimates
Opportunity to Take Share

- Approximately 5,000 independent labs
- Less efficient, higher cost competitors

$55 Billion US Lab Market

Source: Washington G-2 Reports and company estimates
Diversified Payor Mix

- No customer > 9% of revenue
- Limited government exposure

LabCorp U.S. Payor Mix
% of revenue, 2009

- Medicare and Medicaid: 20.2%
- Managed Care Capitated: 7.6%
- Managed Care Fee-for-service: 41.3%
- Client (physicians, hospitals, companies, etc): 3.8%
- Patient: 27.1%
Diversified Test Mix
With Genzyme Genetics acquisition, esoteric testing comprises 40% of revenue
Competitive Position

Scale and Scope

• National infrastructure
• Broad test offering
• Managed care contracts
• Economies of scale

Primary LabCorp Testing Locations*
Esoteric Lab Locations
(CET, CMBP, Dianon, Esoterix, Monogram Biosciences, NGI, OTS, US Labs, Viromed)
Competitive Position

Managed Care Relationships

• Exclusive national laboratory for UnitedHealthcare
• Sole national strategic partner for WellPoint
• Significant national plans recently renewed or extended on a multi-year basis, including WellPoint, Cigna and Humana
• Contracted with numerous local and regional anchor plans
Scientific Leadership

- Introduction of new tests
- Acquisitions and licensing
- Collaborations with leading companies and academic institutions

<table>
<thead>
<tr>
<th>Partner</th>
<th>Clinical Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARCA biopharma</td>
<td>Companion Diagnostics (Cardiovascular Disease)</td>
</tr>
<tr>
<td>BG Medicine</td>
<td>Cardiovascular Disease</td>
</tr>
<tr>
<td>Celera Diagnostics</td>
<td>Breast Cancer</td>
</tr>
<tr>
<td>Duke University</td>
<td>Joint Venture in biomarker development</td>
</tr>
<tr>
<td>Duke University</td>
<td>Lung Cancer</td>
</tr>
<tr>
<td>Exact Sciences</td>
<td>Colon Cancer</td>
</tr>
<tr>
<td>Intema Ltd.</td>
<td>Prenatal Testing</td>
</tr>
<tr>
<td>Johns Hopkins</td>
<td>Melanoma</td>
</tr>
<tr>
<td>MDxHealth</td>
<td>Companion Diagnostics (Oncology)</td>
</tr>
<tr>
<td>Medco Health Solutions</td>
<td>Companion Diagnostics (Research)</td>
</tr>
<tr>
<td>Merck</td>
<td>Companion Diagnostics (Infectious Disease)</td>
</tr>
<tr>
<td>On-Q-ity</td>
<td>Circulating tumor cells</td>
</tr>
<tr>
<td>University of Minnesota</td>
<td>Lupus</td>
</tr>
<tr>
<td>Veridex</td>
<td>Prostate Cancer</td>
</tr>
<tr>
<td>Yale University</td>
<td>Ovarian Cancer (exclusive)</td>
</tr>
</tbody>
</table>
Competitive Position

Most Efficient and Lowest Cost Provider

- Standardized lab and billing IT systems
- Automation of pre-analytics
- Supply chain optimization
- Sysmex fully automated hematology operations
- Gross margin improvement
- Bad debt reduction of 50bp in the first half of 2010
2010 Accomplishments

Our Results

• Profitable revenue growth
  • Empire contract
  • Esoteric growth
  • Acquisitions
• Improved IT and client connectivity
  • LabCorp Beacon
  • Enhanced experience for physicians and patients
• Continued scientific leadership
  • Clearstone collaboration
  • IL-28B
  • New Monogram assays
• Maintained price
  • Managed care stability
  • Strong YTD 2010 results
Our Focus

- Operating objectives
  - Genzyme integration
  - LabCorp Beacon rollout
  - Continue scientific leadership
- Financial objectives
  - Profitable revenue growth
  - Maintain price
  - Control costs
Acquisition Rationale

• Creates the premier genetics and oncology business in the industry
• Builds on our strategy of leadership in personalized medicine
• Generates revenue opportunities
  • Selling LabCorp’s test menu to Genzyme accounts
  • Selling Genzyme’s test menu to LabCorp accounts
  • Genzyme customer access to LabCorp’s convenient PSC network
  • Expanded use of genetic counselors
• Creates cost synergies
  • Logistics
  • Specimen collection
  • G&A
  • Facility overlap
Increasing Importance of Genetics

- Preconception
- Pre – and post – natal
- Identification of disease carriers
- Identification of disease predisposition
- Diagnosis of genetically caused or influenced conditions (e.g., developmental delay)
- Disease prognosis and treatment (especially cancer)
Increasing Importance of Oncology

• More sophisticated methods of cancer testing complement traditional biopsies
• Value of diagnostics for disease prognosis, and monitoring of progression and recurrence
• Critical role of testing in therapy selection
2011 Priorities - Beacon Rollout

Intuitive Order Entry

- **Streamlined Ordering**
  Provider, Diagnosis, Test and Collection information are all displayed in a single screen

- **Requisition and Account Logic**
  Automatically generates requisitions with appropriate account numbers

- **Key Time-saving Features**
  - Send to PSC
  - Standing orders
  - Electronic add-on testing
  - User-defined pick lists
AccuDraw Integration

- Reduce Errors
- Reduce Training Time
- Proven Results
  Success in LabCorp Patient Service Centers will be extended to customers
2011 Priorities – Beacon Rollout

Unified Results

- **Centralizes Lab Connectivity**
  View lab reports from DIANON Systems, Esoterix, LabCorp, Litholink, USLabs, and CMBP

- **Share Results**
  Email, fax, print and annotations make it easy to share critical information

- **Visual Cues**
  Supports physician decision making, enhances the timeliness of patient care and facilitates follow-up with abnormal results in red and unread reports in bold
Results on the Go

- **Clear, Concise Reports**
  Physicians and staff can quickly access results via iPhone® or iPad™ including alerts for abnormal or critical lab results

- **Connect to Patients**
  Access patient demographics directly from the results for phone or email follow up
Trends & Analytics

- **One-Click Trending**
  Physicians and staff can quickly view a single test or analyte for one patient and the trended history for that patient.

- **Sort and Filter Results**
  Providers can filter their entire patient population on demographics and test results to identify trends and patients at risk.

- **View Lab History**
2011 Priorities – Scientific Leadership

Continue Scientific Leadership

- Recent offerings in companion diagnostics and personalized medicine
  - IL-28B
  - K-RAS
  - HLA-B* 5701
  - BRAF Gene Mutation Detection
  - EGFR Mutation Analysis
  - CYP 450 2C19
  - Trofile® (CCR5 Tropism)
  - PhenoSense®, PhenoSense GT®, HERmark®

- Outcome Improvement Programs
  - CKD program
  - Litholink kidney stone program

- Clearstone collaboration
  - Global clinical trials capability
  - Presence in China

“K-RAS testing should be routinely conducted in all colorectal cancer patients immediately after diagnosis to ensure the best treatment strategies for the individual Patient”

– Dr. Eric Van Cutsem, presenter at the June 2008 American Society of Clinical Oncology meeting

FDA recommends genetic screening prior to treatment with Abacavir

ROCKVILLE, Md -- July 24, 2008 -- The US Food and Drug Administration (FDA) has issued an alert regarding serious, and sometimes fatal, hypersensitivity reactions (HSRs) caused by abacavir (Ziagen) therapy in patients with a particular human leukocyte antigen (HLA) allele, HLA-B* 5701.

Genetic tests for HLA-B*5701 are already available, and all patients should be screened for the HLA-B*5701 allele before starting or restarting treatment with abacavir or abacavir-containing medications.

“FDA has approved the expanded use of Selzentry… to include adult patients with CCR5-tropic HIV-1 virus who are starting treatment for the first time.”

Excellent Performance

Revenue and EPS Growth

- 5-year revenue CAGR of 9%
- 5-year EPS CAGR of 15%

![Revenue and EPS Growth: 2004 – 2009](chart)

(1) Excluding the $0.09 per diluted share impact in 2005 of restructuring and other special charges, and a non-recurring investment loss; excluding the $0.06 per diluted share impact in 2006 of restructuring and other special charges; excluding the $0.25 per diluted share impact in 2007 of restructuring and other special charges; excluding the $0.44 per diluted share impact in 2008 of restructuring and other special charges; excluding the ($0.09) per diluted share impact in 2009 of restructuring and other special charges.

(2) EPS, as presented, represents adjusted, non-GAAP financial measures. Diluted EPS, as reported in the Company’s Annual Report were: $2.45 in 2004; $2.71 in 2005; $3.24 in 2006; $3.93 in 2007; $4.16 in 2008; and $4.98 in 2009.
Leading Returns

- Leading returns
- Leading EBIT margin

LabCorp ROE 2004 - 2009
Cash Flow

- 5-year FCF CAGR of 11%
- Strategic acquisitions
- $2.0 B+ share repurchase over last three years

Note: $ in Millions

Note: Free Cash Flow is a non-GAAP metric
Excellent Performance

Free Cash Flow Per Share
• 5-year FCF Per Share CAGR of 18%
• FCF Yield ranged from approximately 8% to 10% in 2010

Note: Free Cash Flow Per Share and Free Cash Flow Yield are non-GAAP metrics
FCF Yield range noted above was calculated using trailing twelve month Free Cash Flow, weighted average diluted share counts and closing stock prices during 2010
### Third Quarter and YTD 2010 Results

<table>
<thead>
<tr>
<th></th>
<th>Three Months Ended Sep 30,</th>
<th>Nine Months Ended Sep 30,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2010</td>
<td>2009</td>
</tr>
<tr>
<td>Revenue (1)</td>
<td>$1,276.5</td>
<td>$1,185.1</td>
</tr>
<tr>
<td>Adjusted Operating Income</td>
<td>$250.1</td>
<td>$237.6</td>
</tr>
<tr>
<td>Adjusted Operating Income Margin</td>
<td>19.6%</td>
<td>20.0%</td>
</tr>
<tr>
<td>Adjusted EPS (1)</td>
<td>$1.47</td>
<td>$1.22</td>
</tr>
<tr>
<td>Operating Cash Flow</td>
<td>$176.2</td>
<td>$246.4</td>
</tr>
<tr>
<td>Less: Capital Expenditures</td>
<td>($34.3)</td>
<td>($22.7)</td>
</tr>
<tr>
<td>Free Cash Flow</td>
<td>$141.9</td>
<td>$223.7</td>
</tr>
</tbody>
</table>

(1) During the first quarter of 2010 inclement weather reduced revenue by an estimated $23 million and EPS by approximately eight cents.
Key Points

- Critical position in health care delivery system
- Attractive market
- Strong competitive position - well positioned to gain share
- Leadership in personalized medicine
- Excellent cash flow
- Strong balance sheet

Source: Deloitte (OAML)
Reconciliation of Non-GAAP Financial Measures

(In millions, except per share data)

<table>
<thead>
<tr>
<th></th>
<th>Three Months Ended Sep 30,</th>
<th></th>
<th>Nine Months Ended Sep 30,</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2010</td>
<td>2009</td>
<td></td>
<td>2010</td>
</tr>
<tr>
<td>Adjusted Operating Income</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operating income</td>
<td>$235.3</td>
<td>$234.9</td>
<td></td>
<td>$740.0</td>
</tr>
<tr>
<td>Restructuring and other special charges (1) (2)</td>
<td>$14.8</td>
<td>$2.7</td>
<td></td>
<td>$24.2</td>
</tr>
<tr>
<td>Adjusted operating income</td>
<td>$250.1</td>
<td>$237.6</td>
<td></td>
<td>$764.2</td>
</tr>
<tr>
<td>Adjusted EPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diluted earnings per common share</td>
<td>$1.34</td>
<td>$1.21</td>
<td></td>
<td>$4.05</td>
</tr>
<tr>
<td>Impact of restructuring and other special charges (1) (2)</td>
<td>$0.13</td>
<td>$0.01</td>
<td></td>
<td>$0.18</td>
</tr>
<tr>
<td>Adjusted EPS</td>
<td>$1.47</td>
<td>$1.22</td>
<td></td>
<td>$4.23</td>
</tr>
</tbody>
</table>

1) During the third quarter of 2010, the Company recorded restructuring and other special charges of $21.8 million, consisting of $10.9 million in professional fees and expenses associated with recent acquisitions; $7.0 million in bridge financing fees associated with the signing of an asset purchase agreement for Genzyme Genetics; and $3.9 million in severance related liabilities associated with workforce reduction initiatives. The after tax impact of these charges decreased net earnings for the three months ended September 30, 2010, by $13.4 million and diluted earnings per share by $0.13 ($13.4 million divided by 104.1 million shares).

During the first quarter of 2010, the Company recorded net charges of $9.3 million relating to severance payments and the closing of redundant and underutilized facilities as well as the write-off of development costs incurred on systems abandoned during the quarter.

The after tax impact of these combined charges decreased net earnings for the nine months ended September 30, 2010, by $19.1 million and diluted earnings per share by $0.18 ($19.1 million divided by 105.4 million shares).

2) During the third quarter of 2009, the Company recorded a charge of approximately $2.7 million representing fees and expenses associated with its acquisition of Monogram Biosciences. The after tax impact of this charge reduced net earnings for the three months ended September 30, 2009, by $1.6 million and diluted earnings per share by $0.01 ($1.6 million divided by 108.8 million shares).

During the second quarter of 2009, the Company recorded net charges of approximately $10.2 million ($6.1 million after tax) related to actions directed at reducing the Company’s redundant and underutilized facilities along with the related work force.

The after tax impact of these combined charges reduced net earnings for the nine months ended September 30, 2009, by $7.7 million and diluted earnings per share by $0.07 for the nine months ended September 30, 2009 ($7.7 million divided by 109.1).
Laboratory Corporation of America
Other Financial Information
FY 2009 and Q1 - Q3 2010
($ in millions)

<table>
<thead>
<tr>
<th></th>
<th>Q1 09</th>
<th>Q2 09</th>
<th>Q3 09</th>
<th>Q4 09</th>
<th>Q1 10</th>
<th>Q2 10</th>
<th>Q3 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bad debt as a percentage of sales</td>
<td>5.30%</td>
<td>5.30%</td>
<td>5.30%</td>
<td>5.30%</td>
<td>5.05%</td>
<td>4.80%</td>
<td>4.80%</td>
</tr>
<tr>
<td>Days sales outstanding</td>
<td>52</td>
<td>50</td>
<td>48</td>
<td>44</td>
<td>46</td>
<td>45</td>
<td>44</td>
</tr>
<tr>
<td>A/R coverage (Allow. for Doubtful Accts. / A/R)</td>
<td>19.5%</td>
<td>20.6%</td>
<td>21.9%</td>
<td>23.2%</td>
<td>21.7%</td>
<td>20.7%</td>
<td>20.4%</td>
</tr>
</tbody>
</table>